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Abstract Long PLUNC1 (LPLUNC1, C20orf114) is a
member of a family of poorly described proteins (PLUNCS)
expressed in the upper respiratory tract and oral cavity,
which may function in host defence. Although it is one of
the most highly expressed genes in the upper airways and
has been identiWed in sputum and nasal secretions by proteo-
mic studies, localisation of LPLUNC1 protein has not yet
been described. We developed aYnity puriWed antibodies
and localised the protein in tissues of the human respiratory
tract, oro- and nasopharynx. We have complemented these
studies with analysis of LPLUNC1 expression in primary
human lung cell cultures and used Western blotting to study
the protein in cell culture secretions and in BAL. LPLUNC1
is a product of a population of goblet cells in the airway epi-
thelium and nasal passages and is also present in airway sub-
mucosal glands and minor glands of the oral and nasal
cavities. The protein is not expressed in peripheral lung epi-
thelial cells. LPLUNC1 is present in bronchoalveolar lavage
Xuid as two glycosylated isoforms and primary airway epi-
thelial cells produce identical proteins as they undergo
mucociliary diVerentiation. Our results suggest that LPLUNC1
is an abundant, secreted product of goblet cells and minor
mucosal glands of the respiratory tract and oral cavity and
suggest that the protein functions in the complex milieu that
protects the mucosal surfaces in these locations.
Keywords LPLUNC1 · Airway · Glands · Goblet cells · 
Immunohistochemistry · Innate immunity
Background
Palate lung nasal epithelium clone (PLUNC) was Wrst
described in the nasal epithelium of the mouse embryo and
the trachea/bronchi of adult mice (Weston et al. 1999). We
made the key observation that PLUNC belongs to a family
of nine genes in a single locus on human chromosome
20q11 (Bingle and Craven 2002, 2004; Bingle et al. 2004)
and showed that they make up the largest branch of a lipid
transfer protein family that includes phospholipid transfer
protein (PLTP), cholesterol ester transfer protein
(CETP), bactericidal permeability increasing protein (BPI)
and LPS-binding protein (LBP) (Bingle et al. 2004).
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Structural similarity across the PLUNC/BPI family sug-
gests that these proteins function by binding lipid mole-
cules (Beamer et al. 1997; Bingle and Craven 2004;
Masson et al. 2009) and this led us to suggest that PLUNCs
may share host defence functions with BPI and LBP
(Bingle and Craven 2002). It is now generally accepted that
PLUNCs fulWl a host defence function (Canny and Levy
2008) but in reality compelling functional data on members
of this family has not been forthcoming. However, our
genomic studies have shown that rapid evolution has pro-
duced a distinct repertoire of PLUNC genes in mammals
characterised by low sequence similarity, an observation
that is often found in host defence protein families (Bingle
et al. 2004; Wheeler et al. 2007). The limited data which
exists indicates that these genes are predominantly
expressed in locations where innate defence is a major
requirement, namely in the nasal, tracheal and bronchial
passages as well as in major salivary glands and minor
mucosal glands of the oral cavity (Weston et al. 1999;
Bingle and Craven 2002; Wheeler et al. 2002; Sung et al.
2002; Di et al. 2003; LeClair et al. 2004; Bingle et al. 2004;
Geetha et al. 2005; Wheeler et al. 2007). The prototypic
two BPI-domain-containing protein, LPLUNC1 (or
C20orf114), along with the founding family member
SPLUNC1 (PLUNC), are highly expressed in the upper
respiratory tract (Weston et al. 1999; Bingle and Bingle
2000; Bingle and Craven 2002; Di et al. 2003) and are
attracting increased attention through their identiWcation in
many genomic and proteomic studies (Barnes et al. 2008).
Importantly, LPLUNC1 and SPLUNC1 are two of the
members of this family that are present in all mammals
(Bingle et al. 2004; Wheeler et al. 2007). There are no pub-
lished studies on the function and localisation of LPLUNC1,
however, proteomic studies have identiWed it in nasal secre-
tions, bronchoalveolar lavage (BAL) and sputum (Casado et al.
2005; Wu et al. 2005; Nicholas et al. 2006) and shown that it is
a major secreted product of cultured tracheobronchial epithe-
lial (TBE) cells (Candiano et al. 2007; Kesimer et al. 2009).
In the present study, we have generated and characterised
antibodies speciWc to human LPLUNC1 and used these to
carry out an extensive analysis of LPLUNC1 expression in
the respiratory tract and oral cavity and have also studied the
production and localisation of the protein in diVerentiated
primary TBE cells cultured at the air–liquid interface (ALI).
Materials and methods
Generation and characterisation of human-speciWc 
LPLUNC1 antibodies
Two aYnity puriWed, peptide-speciWc, polyclonal antibod-
ies were generated in rabbits against human LPLUNC1 by
Eurogentec (Seraing, Belgium) using established methods.
The peptide sequences used corresponded to amino acids,
139–154: (TIRMDTSASGPTRLV) located in the Wrst BPI
domain of LPLUNC1 (for LPLUNC1 antibody “A”) and
the second to amino acids, 472–484: (ASLWKPSSPVSQ)
at the extreme C-terminus of the protein in the second BPI
domain (for LPLUNC1 antibody “B”). These peptides were
chosen so as to have minimal sequence conservation
between man and mouse (Supplementary Figure S1) and no
similarity with other members of the PLUNC family. Bio-
informatic analysis also showed that these epitopes had no
signiWcant sequence identity with any other human pro-
teins.
Expression clones for LPLUNC1 proteins (both mouse
and human) in pcDNA5-frt-V5-His-Topo (Invitrogen) were
used in the characterisation of the antibodies. Constructs
were used for coupled in vitro transcription/translation
(IVT) reactions (Promega) as previously described (Bingle
et al. 2005, 2007) and to generate CHO cell lines stably
expressing the proteins. Expression clones for SPLUNC1
and SPLUNC2, produced in the same vector, were used as
controls (Bingle et al. 2005, 2009). 2 l aliquots of IVT
reactions or 5 l of serum free conditioned medium from
CHO cell lines stably expressing PLUNC proteins, were
run on replicate SDS-PAGE gels and Western blotted using
either an anti-V5 antibody (1:500 dilution) (Invitrogen) or
the speciWc LPLUNC1 antibodies (1:2,000 dilution) and
detected as described (Bingle et al. 2005, 2009).
Immunohistochemistry
The tissue used in this study was collected with ethical
approval on a fully anonymous basis only and thus we have
no further patient details. Serial sections (4 m) were cut
from formalin-Wxed and paraYn-embedded tissue as
described (Bingle et al. 2005, 2006). For normal pulmonary
tissues, sections were taken so as to be as representative of
normal architecture as possible, although as all tissues were
removed for medical reasons there was some evidence of
disease in some sections. Sections from the major bronchi
and peripheral lung were cut from >15 cases of histologi-
cally “normal” lung. The slides were stained as previously
described (Bingle et al. 2005, 2007, 2009). LPLUNC1 anti-
bodies were used at a Wnal dilution of 1:100 (LPLUNC1A)
or 1:600 (LPLUNC1B) following antigen retrieval using
tri-sodium citrate in a microwave for 8 min (Bingle et al.
2007). Control sections were stained in the absence of
either primary or secondary antibody. Antibodies against
human SPLUNC1 (Wnal dilution 1:300) and human mucin
5AC (MUC5AC, a gift of Dr David Thornton, University
of Manchester, Wnal dilution 1:500) were used as described
(Campos et al. 2004; Bingle et al. 2007; Kirkham et al.
2008).
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Cell culture, RNA extraction and RT-PCR
Human TBE cells were cultured at an ALI as described pre-
viously (Nlend et al. 2002) using protocols approved by the
local institutional review board. RNA extraction, RT-PCR
and product validation was performed as described (Bingle
et al. 2006, 2007) using the following primers for
LPLUNC1 F 5 CCC TGC CCA ATC TAG TGA AA 3,
LPLUNC1 R 5 TCA CCT TTC CCT GTG AGT CG 3
and Actin F 5 CTA CAA TGA GCT GCG TGT GG
3, Actin R 5 AAG GAA GGC TGG AAG AGT GC 3.
The SPLUNC1, SLPI, ElaWn and CCSP primers have been
described previously (Bingle et al. 2006, 2007). RT-minus
PCR reactions were run as negative controls for all
experiments.
Immunocytochemistry
After harvesting apical secretions with PBS, ALI TBE cul-
ture Wlters were Wxed with 50% acetone/50% methanol for
2 min at ¡20°C, blocked with 1% BSA for 1 h, and incu-
bated overnight with anti-LPLUNC1 antibodies (1:500
PBS–1% BSA) at 4°C. All subsequent steps were done at
room temperature. After washing with PBS (3£), Wlters
were incubated with a polyclonal goat anti-rabbit IgG
labelled with Alexa Fluor 555 (1:5,000 PBS–1% BSA,
Molecular Probes) for 1 h. Culture Wlters were sliced and
incubated with either mouse anti-human MUC5AC IgG
(1:100 PBS–1% BSA, Chemicon International) or mouse
anti-human acetylated tubulin IgG (1:500 PBS–1% BSA,
Sigma) for visualization of mucous or ciliated cells, respec-
tively. In addition, some slides were incubated with goat
anti-human SPLUNC1 IgG (1:100 PBS–1% BSA, R&D
Systems). Appropriate second antibodies labelled with
either Alexa Fluor 488, Alexa Fluor 555 or Cy5 (1:500 in
PBS–1% BSA, all from Molecular Probes) were added for
1 h. 4-6-Diamidino-2-phenylindole (DAPI, 1:1,000) was
added to the last wash for nuclear staining. Filters were
placed in glass slides for visualization with a Zeiss LSM-
510 confocal laser-scanning microscope in the University
of Miami Analytical Imaging Core Facility.
Western blotting of cell culture secretions 
and Bronchoalveolar lavage
Apical secretions were collected, every 2–3 days, from
diVerentiated TBE cells cultured at the ALI, by washing
each well of a 12 well plate with 100 l of PBS. Pooled
samples were centrifuged at 600£g to remove cellular
debris and 5 l aliquots used for Western blotting as out-
lined above. BAL samples were obtained by instilling
60 ml of normal saline in either the non-diseased middle
lobe or lingula from subjects undergoing clinically indi-
cated bronchoscopy, under a protocol approved by the
University of Miami’s Institutional Review Board. 15 l of
BALs were subjected to Western blotting. Aliquots of ALI
cell culture secretions and BAL were digested overnight
with PNGase F (NEB) according to the manufacturer’s
instructions and Western blotted.
Results
Validation of LPLUNC1 antibodies
To study the localisation of LPLUNC1 we generated two
aYnity puriWed antibodies using unique peptide epitopes.
The antibodies were validated by Western blotting with
recombinant proteins (LPLUNC1, SPLUNC1 and
SPLUNC2) produced both by in vitro transcription/transla-
tion and by transfected mammalian cells. An example of
this validation is presented. The LPLUNC1B antibody
recognised LPLUNC1 produced both in vitro and in
mammalian cells (Fig. 1a) and does not cross react with
SPLUNC1 or SPLUNC2 (Fig. 1b). In vitro translated
LPLUNC1 protein migrates faster than that secreted by the
CHO cells (Fig. 1a). The LPLUNC1A antibody reacted in a
similar manner (results not shown).
LPLUNC1 is localised in a population of goblet cells 
in the upper airways and in submucosal and minor mucosal 
glands
Previously we observed expression of LPLUNC1 in tissue
from the nasal passages, trachea and lung (Bingle and
Craven 2002), so initially used tissues from these regions
for our immunohistochemical studies. Two distinct areas of
staining were seen in sections from the maxillary sinus
(antral) mucosa; intense staining in cells within the respira-
tory epithelium and also within seromucous tubules and
acini of minor mucosal glands (Fig. 2a), the luminal con-
tents of the ducts also stained. Higher magniWcation images
show that LPLUNC1 appears to be present in epithelial
cells with a characteristic “goblet cell” phenotype (Fig. 2b).
Not all sinus mucosa samples contained signiWcant goblet
cells and in these cases staining of LPLUNC1 was much
less intense (not shown). In tissues with squamous metapla-
sia we only saw signiWcant staining in the minor glands
(Fig. 2c) and it was predominantly serous cells that exhib-
ited strong staining.
In the trachea and central bronchi the most prominent
staining was seen in a population of what appeared to be
surface goblet cells and in sub-mucosal glands (Fig. 2d). In
a number of cases we noted the most intense staining in
cells of the submucosal duct and in epithelial regions where
the duct entered the airway. Staining was also seen in
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epithelial cells of smaller airways (those without cartilage
and submucosal glands, Fig. 2e, f). Importantly LPLUNC1
staining was never seen in the alveolar epithelium (Fig. 2f)
nor were we able to detect speciWc staining in endothelial
cells or in inXammatory cells, including alveolar
macrophages (results not shown). To ensure speciWcity of
the antibodies we stained closely cut sections with both
antibodies. They both stained cells of the seromucous
tubules in submucosal glands (Fig. 2h, i) suggesting that
they both recognise the same protein. Mucous cells in the
airway submucosal glands did not stain. Additional anti-
bodies to SPLUNC2 generated and puriWed at the same
time (Bingle et al. 2009) as the LPLUNC1 antibodies failed
to show any staining in the lung sections (results not
shown) and sections stained without the addition of primary
or secondary antibodies were also negative for staining
(results not shown) further supporting our belief that these
antibodies are valid reagents for the speciWc detection of
human LPLUNC1.
Localisation of LPLUNC1 was directly compared with
the prototypic family member, SPLUNC1, in the respira-
tory tract; the two proteins are not co-localised (Fig. 3).
LPLUNC1 stained a goblet cell population in the trachea
and smaller airways (Fig. 3a, c) but these were negative for
SPLUNC1 (Fig. 3b, d). In airway submucosal glands a sim-
ilar, essentially mutually exclusive localisation pattern was
seen (Fig. 3e, f), with staining of serous demilunes of the
gland by anti-LPLUNC1 (black arrow, Fig. 3e) but not
SPLUNC1, which only stained mucous tubules within the
gland (red arrow, Fig. 3f). Our results do, however, suggest
that a few cells in submucosal gland ducts may exhibit
co-localisation of both proteins (Fig. 3e, f). We also stained
sections with MUC5A/C to conWrm that the LPLUNC1
positive cells were goblet cells (Fig. 4). However, although
MUC5A/C and LPUNC1 were present in similar locations
in the airways and in submucosal glands not all MUC5A/C
expressing cells were positive for LPLUNC1 suggesting
that it is not a surrogate marker for airway goblet cells.
As mouse Lplunc1 is highly expressed in minor glands
of the tongue (Leclair et al. 2004) we extended our studies
to minor salivary glands of the oral cavity (Fig. 5). The
keratinised epithelial surface of the tongue and the muscle
was uniformly negative for LPLUNC1 (results not shown).
However, in the posterior portion of tongue some of the
minor glands demonstrated strong LPLUNC1 staining in
the seromucous acini and within ductular cells (Fig. 5a),
whereas others (more mucous-like) did not (Fig. 5b). Minor
glands of the vallecular region of the tongue, associated
with tonsil, also stained with LPLUNC1 (Fig. 5c). The
majority of the tonsil tissue, including tonsillar crypts or
germinal centres did not stain (results not shown). Interest-
ingly, in minor glands associated with the tonsil we saw
co-localisation with SPLUNC1 (Fig. 5d). In all cases the
staining pattern was identical irrespective of which
LPLUNC1 antibody was used (results not shown).
LPLUNC1 is secreted from goblet cells in diVerentiated 
TBE cell cultures as a glycosylated protein
On the basis of the in vivo localisation of LPLUNC1, we
used primary human TBE cells to investigate the produc-
tion and secretion of LPLUNC1. Array studies have previ-
ously suggested that LPLUNC1 mRNA is abundantly
expressed in these cells (Ross et al. 2007). LPLUNC1
mRNA expression was readily detected in TBE cells
directly harvested from healthy donor lungs (Fig. 6a, lane
H) but was lost as the cells de-diVerentiated in submerged
cell culture (P1 and P2), as conWrmed by loss of CCSP, a
marker of diVerentiated bronchiolar cells, and the related
Fig. 1 Characterisation of the LPLUNC1 antibody by Western blot-
ting. a V5-epitope tagged LPLUNC1 proteins were generated by cou-
pled in vitro transcription and translation (Ivt-LPLUNC1) or from
conditioned medium from stable CHO expressing cell lines (CHO
LPLUNC1) or control medium (CHO) as outlined in “Materials and
methods”. 2 l of the IVT reaction or 5 l of concentrated conditioned
media was resolved on replicate 12% SDS-PAGE gels and Western
blotted using the LPLUNC1B polyclonal antibody or an antibody to
the V5 epitope as described. The black arrows indicate the positions
of the molecular mass markers. b V5-epitope tagged PLUNC proteins
were generated from conditioned medium from stable CHO express-
ing cell lines, expressing SPLUNC1 a cystine-mutant SPLUNC1
(SPLUNC1m), SPLUNC2 or LPLUNC1 or control medium (Con) as
outlined in “Materials and methods”. 5 l of concentrated conditioned
media was resolved on replicate 12% SDS-PAGE gels and Western
blotted using the LPLUNC1B polyclonal antibody or an antibody to
the V5 epitope as described. The black arrows indicate the positions
of the molecular mass markers
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pulmonary protein SPLUNC1. When the cells were placed
at an ALI they re-diVerentiated, demonstrated by the visual
appearance of cilia (results not shown) and re-expression of
CCSP, and the expression of LPLUNC1 (and SPLUNC1)
increased (Fig. 6a, lane d14). Removal of retinoic acid from
the culture medium of fully diVerentiated cells gradually
results in the development of a squamous phenotype (Yoon
et al. 1997). This was conWrmed by the induction of the
squamous cell marker elaWn (Bingle et al. 2006) and was
associated with a progressive loss of LPLUNC1 expression
that mirrors the previously described loss of SPLUNC1
(Bingle et al. 2007; Fig. 6b). Expression was not com-
pletely lost after 18 days of RA withdrawal suggesting that
the phenotypic alteration was not complete at this time. In
keeping with the localisation of LPLUNC1 in vivo we were
also unable to detect expression or secretion of LPLUNC1
in primary alveolar epithelial cells (results not shown).
Secretion of LPLUNC from ALI cells has not previously
been studied. We sampled the mucous secretions from the
surface of the epithelial cell cultures as they underwent the
Fig. 2 Distribution of 
LPLUNC1 in the respiratory 
tract. Immunohistochemistry for 
LPLUNC1 was performed with 
the LPLUNC1B antibody as de-
scribed in “Materials and meth-
ods”. Sections show staining in 
samples of nasal antral mucosa 
(a–c), trachea (d), bronchial 
airways (e) and bronchiolar 
epithelium (f). Serial sections of 
trachea were stained with both 
antibodies, LPLUNC1A (g) and 
LPLUNC1B (h). The original 
magniWcations of the images 
were t£100 (a, c, d), £200 
(e–h) and £400 (b)
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Fig. 3 LPLUNC1 and SPL-
UNC1 do not co-localise in the 
respiratory tract. Immunohisto-
chemistry was performed as 
described in “Materials and 
methods” for LPLUNC1 (a–e) 
and SPLUNC1 (b, d, f). Sections 
show staining in serial samples 
of airways (a–d) and in an air-
way submucosal gland (e, f). 
The black arrow in e shows a 
serous demilune that is positive 
for LPLUNC1 whereas the red 
arrow in f points to the same 
group of cells that is negative for 
SPLUNC1. The original magni-
Wcations of the images were 
£200 (a, b) and £400 (c–f)
Fig. 4 LPLUNC1 and 
MUC5A/C do not always 
co-localise in the respiratory 
tract. Immunohistochemistry 
was performed as described in 
“Materials and methods” for 
LPLUNC1 (a, c) and MUC5A/C 
(b, d). Sections show staining in 
serial samples of airways (a, d) 
and in an airway submucosal 
gland (c, d). The original magni-
Wcations of the images were 
£200 (a, b) and £400 (c, d)
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process of diVerentiation. LPLUNC1 protein was readily
detectable in the ALI secretions as two distinct immunore-
active products (Fig. 7a). Levels of protein appeared to
increase as the cells diVerentiated; these results were con-
Wrmed in a second set of samples from a diVerent donor.
Both protein bands were of greater size than the predicted
size, similar to the protein produced by CHO cells (Fig. 1).
This suggested that the protein undergoes some form of
post-translational modiWcation and to investigate this we
carried out de-glycosylation studies using PNGaseF (which
hydrolyses most N-glycan chains). Both immunoreactive
bands reduced in size following PNGase treatment suggest-
ing that LPLUNC1 secreted by ALI cells is N-glycosylated
(Fig. 7b). BAL treated with PNGase demonstrated similar
immunoreactive LPLUNC1 bands, suggesting that the pro-
tein product of the diVerentiated ALI cells is glycosylated
in the same way as that secreted into the airways in vivo
(Fig. 7b). Identical results were also seen when replicate
blots from both studies were Western blotted using the
LPLUNC1A antibody (results not shown). Importantly, we
also failed to show that LPLUNC1 was subjected to any
further proteolytic cleavage in either sample as no
additional, smaller, immunoreactive bands were seen
(Fig. 7a, b).
Immunocytochemistry was used to identify the speciWc
site of production of LPLUNC1 in TBE cell cultures. This
indicated that LPLUNC1 is present in a population of non-
ciliated cells (Fig. 8a) whilst the population of cells that
secrete SPLUNC1 is greater and for the most part diVerent
from the cells that secrete LPLUNC1. LPLUNC1 was again
shown to be present in a subpopulation of MUC5AC
staining cells (Fig. 8b). Importantly this analysis suggests
that not all LPLUNC1 expressing cells stain with
MUC5AC and vice versa.
Discussion
Since our original description of LPLUNC1 as the proto-
typic two BPI-domain-containing PLUNC family member
(Bingle and Craven 2002), no studies have addressed the
localisation or secretion of the protein. In the present study,
we used highly speciWc antibodies to localise expression of
LPLUNC1 in the upper respiratory tract, nasal and oral
cavities. We took great care to ensure that the antibodies
recognise only LPLUNC1 by choosing peptides that had no
sequence conservation with other PLUNC family members
and that are not conserved in orthologues from rodent spe-
cies (Bingle and Craven 2002; Bingle et al. 2004). Further-
more these epitopes are not present in any other mouse
protein. The fact that both antibodies stained proteins in the
same cells in the tissue sections (Fig. 2) and recognised the
same protein bands in Western blotting of ALI secretions
and BAL Xuid, lend further support of our suggestion that
they are recognising human LPLUNC1 speciWcally. The
antibodies indicate that the protein is abundantly expressed
in a population of goblet cells in the upper respiratory tract
and that the protein is strongly expressed in airway submu-
cosal glands and a range of minor glands present in the oral
cavity and nasopharynx. Our Western blotting studies,
which identiWed the protein in BAL Xuid, provide strong
evidence for secretion of LPLUNC1 into mucosal lining
Fig. 5 Distribution of LPL-
UNC1 in minor glands of the 
oral cavity. Immunohistochem-
istry for LPLUNC1 and 
SPLUNC1 was performed as 
described in “Materials and 
methods”. Sections show stain-
ing in a seromucous gland of in 
the tongue (a) but no staining in 
a minor mucus gland in the 
proximal tongue (b). Serial 
sections of minor glands sur-
rounding the palatine tonsils 
show that both LPLUNC1 (c) 
and SPLUNC1 (d) are positive 
in the same region. The original 
magniWcations of the 
images were £200 (a, b) 
and £400 (c, d)
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Xuids and also supports a number of proteomic studies that
have reported the protein in BAL, sputum and in nasal
secretions (Casado et al. 2005; Wu et al. 2005; Nicholas
et al. 2006; Candiano et al. 2007; Kesimer et al. 2009).
Although LPLUNC1 appears to be present in a popula-
tion of goblet cells in the airways in these non-diseased
samples it is not present in all goblet cells and is most com-
monly seen in those that are closely associated with the
junction of the submucosal gland duct and within the duct
itself. Thus, LPLUNC1 is not a surrogate marker for airway
goblet cells especially as in the normal airways there are
clearly a signiWcant number of MUC5AC containing cells
that are negative for LPLUNC1. It is possible that the lack
of staining seen in some goblet cells may reXect the fact
that the protein has been secreted into the airway lumen.
Further studies are required to identify if these LPLUNC1
positive goblet cells exhibit any additional unique charac-
teristics. Mouse lplunc1 RNA has been shown to be
Fig. 6 LPLUNC1 is expressed in primary tracheal cells and cells
diVerentiated at the ALI. a Expression of LPLUNC1 was studied by
PCR using freshly harvested human tracheal cells (H) and samples tak-
en from the cultures at two stages (P1, P2) as the cells were established
at an air–liquid interface (ALI). Expression of SPLUNC1, the non-cil-
iated tracheal cell marker CCSP and actin (as a PCR control) was also
monitored in the same samples. b Expression of LPLUNC1 was stud-
ied by PCR in samples of primary tracheobronchial epithelial cells dur-
ing retinoic acid depletion and the subsequent loss of the diVerentiated
phenotype. ALI cells were established using standard growth condi-
tions in medium containing 50 nM all trans retinoic acid (RA). After
14 days in culture RA was removed from the medium of one group of
cells and culture was continued for an additional 18 days. Expression
of LPLUNC1 and SPLUNC1 was investigated by RT-PCR with exon
spanning primer pairs as described in “Materials and methods” with
primers to SLPI and elaWn serving as a positive controls. RT-negative
PCR reactions were run for each experiment and representative RCR
products were cloned and sequenced for conWrmation. The data in both
panels represents one of three sets of experiments performed with cells
from diVerent donors
Fig. 7 LPLUNC1 is secreted into the apical Xuid as a glycosylated
protein identical to that found in BAL Xuid. a Secretion of LPLUNC1
into apical secretions harvested from ALI cell cultures was shown by
Western blotting using the LPLUNC1B antibody. Samples were har-
vested from the cells every 2–3 days. The positions of the molecular
mass markers are indicated by the black arrows. The data is represen-
tative of two diVerent experiments. b Deglycosylation studies were
performed using BAL Xuid and ALI secretions as described in “Mate-
rials and methods”. The resultant reaction products were subjected to
Western blotting and detected with the LPLUNC1B antibody. The
positions of the molecular mass markers are indicated by the black ar-
rows
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elevated in multiple mouse models associated with
increased goblet cells (Barnes et al. 2008) and we are pres-
ently evaluating if all airway goblet cells human diseased
human lung tissues stain for the protein.
Importantly our studies have shown that LPLUNC1 is
present in a diVerent airway cell population than the related
protein, SPLUNC1, previously shown to be present in non-
ciliated, non-goblet-cells (Bingle et al. 2005, 2007). It is
clear that these cells do not express LPLUNC1. The situa-
tion is somewhat diVerent in some minor mucosal glands
where, for example, the minor seromucous glands sur-
rounding the palatine tonsils co-express both proteins.
Interestingly these particular glands also express
SPLUNC2, the major salivary gland expressed family
member (Bingle et al. 2009), suggesting that at least in
some situations minor gland cells contain the appropriate
regulatory machinery to support expression of a range of
diVerent PLUNCs. Our analysis has focused on tissues of
the respiratory tract and oral cavities as this appears to be
the predominant site of LPLUNC1 expression (Bingle and
Craven 2002). Analysis of multiple expression data sets do
not suggest that other tissues that contain abundant goblet
cells, for example the intestines, are major sites of LPL-
UNC1 expression. We did report that stomach expressed
LPLUNC1 (Bingle and Craven 2002) and that expression
was also seen in the developing mouse gut (LeClair et al.
2004). More recently LPLUNC1 expression has been
shown to be increased in biopsies form patients with acute
cholera (Flach et al. 2007). Further studies are required to
establish that these tissues do produce the protein.
The mechanisms that govern expression of PLUNCs
have not been elucidated, in part because of the lack of suit-
able cell lines in which to perform these studies. We have
reported SPLUNC1 NCI-H647 cells (Bingle and Bingle
2000), but have been unable to Wnd an established cell line
that supports expression of LPLUNC1 (results not shown).
Our analysis of the ALI TBE cells suggests that this model
system may be a useful one in which to uncover regulatory
mechanisms as they express both LPLUNC1 and
SPLUNC1 and levels of gene expression can be modulated
by the diVerentiation status of the cultures. The ALI cul-
tures further mimicked the situation in the airways in vivo
as LPLUNC1 was found in a population of ‘goblet’ cells, as
judged by the co-expression of MUC5A/C, but expression
of the two markers was not always seen in the same cells.
However, in contrast to this, in vitro expression of
LPLUNC1 was seen in a subpopulation of cells that also
produce SPLUNC1 suggesting that this culture model may
support some uncoupling of gene expression not seen in
“normal” airways. SPLUNC1 was still seen in more cells
than LPLUNC1. These studies conWrm that ALI TBE cells
maybe useful tools in which to study the regulation of
LPLUNC1 and SPLUNC1 gene expression.
The LPLUNC1 secreted by TBE cells was glycosylated
in a manner similar to that found in BAL samples. N-
glycosylated isoforms of LPLUNC1 have also been
described in saliva (Ramachandra et al. 2008) and it seems
likely that this post-translational modiWcation, and thus the
glycosylation status, is functionally important for the bio-
logical activity of LPLUNC1. Previous studies have also
Fig. 8 LPLUNC1 is localised in non-ciliated MUC5AC positive cells
in TBE ALI cell cultures. Confocal IF microscopy was performed on
diVerentiated ALI cultures as described in “Materials and methods” for
LPLUNC1, SPLUNC1, tubulin and MUC5A/C as described. a LPL-
UNC1 and SPLUNC1 are localised in non-ciliated cells. Ciliated cells
were identiWed with IgG anti-acetylated tubulin present in ciliary struc-
tures. The population of SPLUNC1-positive cells is more abundant
than LPLUNC1 positive cells. b LPLUNC1 is present in some
MUC5AC positive cells. All pictures were taken with a Zeiss LSM-
510 confocal microscope, at £40 with a £2 digital zoom
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shown that other PLUNCs, including both SPLUNC1 and
the salivary enriched protein, SPLUNC2/psp, are also sub-
jected to signiWcant post-translational modiWcations (Mirels
et al. 1998; Ghafouri et al. 2004; Bingle et al. 2009) sug-
gesting that it is a common feature of this family of pro-
teins. Our Western blotting studies also suggest that
LPLUNC1 is not subject of signiWcant proteolytic process-
ing in normal airways secretions. We could not detect any
smaller proteolytic fragments either the ALI secretions or
the BAL Xuid when samples were probed with either anti-
body. It remains to be seen if a similar situation is seen in
samples from lung disease.
Our studies suggest that LPLUNC1 is expressed in a
goblet cell population and thus it seems likely that altera-
tions of LPLUNC1 localisation and production may be
found in lung diseases associated with increase numbers of
goblet cells. This suggestion is further supported by the
observation that Lplunc1 is elevated in multiple array stud-
ies of mouse models of lung diseases (Barnes et al. 2008) in
which goblet cell number are known to be increased. We
have previously reported an increase in SPLUNC1 protein
production by airway epithelial cells in severe cystic Wbro-
sis (Bingle et al. 2007) due to a phenotypic alteration in the
airways in such patients and are presently evaluating
LPUNC1 expression in this and a series of other human dis-
ease sample sets.
In summary, we have localised LPLUNC1 to a subset of
goblet cells within the airways, in the submucosal glands of
the upper airways, as well as in minor glands in the nose,
sinuses, posterior tongue and tonsil. LPLUNC1 is present in
BAL Xuid as a glycoprotein and we have shown that expres-
sion and secretion of the protein is increased in TBE cells as
they undergo mucociliary diVerentiation in culture. Although
the function of LPLUNC1 remains to be resolved, our results
suggest that the protein functions in the complex milieu that
protects the mucosal surfaces in these locations.
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